Nelfinavir Mesylate

FDA-approved product (powder, oral), marketed as Viracept.

Registered studies: 50+
Lab records: 0
Pathogens at ≥40%: 3 of 4

Chemical structure

A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

HIV infection
HIV-1 infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group: Protease inhibitors
Anti-infective classification: Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE04

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured

MRSA46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
E. coli42.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
K. pneumoniae34.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nelfinavir Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nelfinavir Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

Condition

Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection
NCT00205283 · start 2003-08
Registered record
Registry ID
NCT00205283
Conditions
HIV Infections
Interventions
Nelfinavir
Study type
INTERVENTIONAL
Phase
Not applicable
Registry status
Completed
Start
2003-08
Completion
2005-08-01
Enrolment
20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections
InterventionNelfinavir
PhaseNot applicable
Registry statusCompleted
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
NCT00042289 · start 2003-06-09
Registered record
Registry ID
NCT00042289
Conditions
HIV Infections
Interventions
atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
Study type
OBSERVATIONAL
Phase
Not recorded
Registry status
Completed
Start
2003-06-09
Completion
2020-09-30
Enrolment
1,578
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections
Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
PhaseNot recorded
Registry statusCompleted
The Effects of HIV Protease Inhibitors in Severe Sepsis
NCT00346580 · start 2003-06
Registered record
Registry ID
NCT00346580
Conditions
Sepsis
Interventions
Nelfinavir
Study type
INTERVENTIONAL
Phase
Phase 1
Registry status
Completed
Start
2003-06
Completion
2005-09
Enrolment
60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSepsis
InterventionNelfinavir
PhasePhase 1
Registry statusCompleted
Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers
NCT02257008 · start 2003-03
Registered record
Registry ID
NCT02257008
Conditions
Healthy
Interventions
BILR 355 BS; Grapefruit juice; Nelfinavir; Atazanavir; Ritonavir
Study type
INTERVENTIONAL
Phase
Phase 1
Registry status
Completed
Start
2003-03
Completion
Not recorded
Enrolment
44
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy
InterventionBILR 355 BS; Grapefruit juice; Nelfinavir; Atazanavir +1 more
PhasePhase 1
Registry statusCompleted
A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea
NCT00650637 · start 2003-01
Registered record
Registry ID
NCT00650637
Conditions
Diarrhea
Interventions
Calcium Carbonate; nelfinavir; lamivudine; loperamide; Calcium carbonate not administered; nelfinavir; lamivudine + zidovudine
Study type
INTERVENTIONAL
Phase
Phase 3
Registry status
Terminated
Start
2003-01
Completion
2003-08
Enrolment
17
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiarrhea
InterventionCalcium Carbonate; nelfinavir; lamivudine; loperamide +3 more
PhasePhase 3
Registry statusTerminated
Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy
NCT00017719 · start 2002-05
Registered record
Registry ID
NCT00017719
Conditions
HIV Infections; Pregnancy
Interventions
Lamivudine; Lamivudine/Zidovudine; Nelfinavir mesylate; Nevirapine; Zidovudine
Study type
INTERVENTIONAL
Phase
Phase 3
Registry status
Completed
Start
2002-05
Completion
2006-03
Enrolment
440
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections; Pregnancy
InterventionLamivudine; Lamivudine/Zidovudine; Nelfinavir mesylate; Nevirapine +1 more
PhasePhase 3
Registry statusCompleted
A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)
NCT00541463 · start 2001-01
Registered record
Registry ID
NCT00541463
Conditions
HIV Infections
Interventions
MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks; Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks
Study type
INTERVENTIONAL
Phase
Phase 2
Registry status
Completed
Start
2001-01
Completion
2003-05
Enrolment
330
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections
InterventionMK0639, indinavir sulfate / Duration of Treatment: 48 Weeks; Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks
PhasePhase 2
Registry statusCompleted
TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB
NCT00023400 · start 2000-02
Registered record
Registry ID
NCT00023400
Conditions
HIV Infections; Tuberculosis
Interventions
Nelfinavir; Rifabutin
Study type
INTERVENTIONAL
Phase
Phase 4
Registry status
Completed
Start
2000-02
Completion
2002-02
Enrolment
20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections; Tuberculosis
InterventionNelfinavir; Rifabutin
PhasePhase 4
Registry statusCompleted
Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy
NCT00004985 · start 2000-01
Registered record
Registry ID
NCT00004985
Conditions
HIV Infections
Interventions
Capravirine; Nelfinavir mesylate
Study type
INTERVENTIONAL
Phase
Phase 2
Registry status
Completed
Start
2000-01
Completion
Not recorded
Enrolment
75
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections
InterventionCapravirine; Nelfinavir mesylate
PhasePhase 2
Registry statusCompleted
A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs
NCT00002442 · start 1999-06
Registered record
Registry ID
NCT00002442
Conditions
HIV Infections
Interventions
Indinavir sulfate; Nelfinavir mesylate; Lamivudine; Stavudine
Study type
INTERVENTIONAL
Phase
Phase 2
Registry status
Completed
Start
1999-06
Completion
Not recorded
Enrolment
Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections
InterventionIndinavir sulfate; Nelfinavir mesylate; Lamivudine; Stavudine
PhasePhase 2
Registry statusCompleted
A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs
NCT00002411 · start 1998-03
Registered record
Registry ID
NCT00002411
Conditions
HIV Infections
Interventions
Nelfinavir mesylate; Lamivudine; Stavudine; Zidovudine; Didanosine
Study type
INTERVENTIONAL
Phase
Not applicable
Registry status
Completed
Start
1998-03
Completion
1999-09
Enrolment
Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections
InterventionNelfinavir mesylate; Lamivudine; Stavudine; Zidovudine +1 more
PhaseNot applicable
Registry statusCompleted
Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma
NCT00003008 · start 1997-12-15
Registered record
Registry ID
NCT00003008
Conditions
Sarcoma
Interventions
indinavir sulfate; nelfinavir mesylate; paclitaxel; ritonavir; saquinavir mesylate
Study type
INTERVENTIONAL
Phase
Phase 2
Registry status
Completed
Start
1997-12-15
Completion
Not recorded
Enrolment
33
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSarcoma
Interventionindinavir sulfate; nelfinavir mesylate; paclitaxel; ritonavir +1 more
PhasePhase 2
Registry statusCompleted
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection
NCT00002176 · start 1997-05
Registered record
Registry ID
NCT00002176
Conditions
HIV Infections
Interventions
Hydroxyurea; Nelfinavir mesylate; Stavudine; Didanosine
Study type
INTERVENTIONAL
Phase
Not applicable
Registry status
Completed
Start
1997-05
Completion
2000-03
Enrolment
Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections
InterventionHydroxyurea; Nelfinavir mesylate; Stavudine; Didanosine
PhaseNot applicable
Registry statusCompleted
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
NCT00000859
Registered record
Registry ID
NCT00000859
Conditions
HIV Infections
Interventions
Indinavir sulfate; Ritonavir; Nelfinavir mesylate
Study type
INTERVENTIONAL
Phase
Not applicable
Registry status
Completed
Start
Not recorded
Completion
2001-12
Enrolment
1,300
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections
InterventionIndinavir sulfate; Ritonavir; Nelfinavir mesylate
PhaseNot applicable
Registry statusCompleted
A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
NCT00000887
Registered record
Registry ID
NCT00000887
Conditions
HIV Infections; Pregnancy
Interventions
Nelfinavir mesylate; Lamivudine; Zidovudine
Study type
INTERVENTIONAL
Phase
Phase 1
Registry status
Completed
Start
Not recorded
Completion
2004-07
Enrolment
24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections; Pregnancy
InterventionNelfinavir mesylate; Lamivudine; Zidovudine
PhasePhase 1
Registry statusCompleted

Existing / approved use

Repurposing investigation

AI-predicted activity

Evidence

Clinical and experimental

Docking

Other medicines to investigate

Registered studies